1 October we become SureStone CapitalSame team, same ABN. Our website and email addresses move to surestone.com.au.
Preparing video
Key points:
Expansion of Technegas installations across 11 University Hospitals sites in the USShift to a leasing and consumables model to build high‑margin recurring revenueGlobal footprint in 67 countries with US clinical guidelines expected to reference Technegas
Cyclopharm’s James McBrayer sets out an upbeat outlook for the company’s proprietary Technegas lung imaging agent, pointing to a new deal with University Hospitals in the United States to roll out systems across 11 sites. McBrayer states this is Cyclopharm’s first “double‑digit” installation agreement in one hit, contrasting it with previous US wins at Massachusetts General, Stanford and Emory, which start with one or two locations and then expand.
McBrayer frames the US as the key growth market, with a differentiated enterprise rollout strategy. Instead of selling gas systems outright, Cyclopharm leases them to avoid capital hurdles for hospitals and focuses on high‑margin consumables, which McBrayer characterises as an annuity‑style revenue stream. He notes the company already operates in 67 countries and claims Technegas is widely regarded as the clinical agent of choice for functional lung ventilation imaging outside the US.
On performance, McBrayer highlights record revenue in the latest half, driven by a 73% jump in US revenue from about $1.1 million to just over $2 million, alongside an increase from 50 to 70 revenue‑generating installations by end‑July. He suggests upcoming US clinical guidelines naming Technegas, plus emerging AI applications using its rich functional imaging data, could further accelerate adoption and support the path to profitability for (ASX:CYC).
